Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
RICHMOND, Calif., April 25, 2017 -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company, today announced that it will release financial and business results for the first quarter 2017 after the close of trading on Tuesday, May 9, 2017. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.
Investors interested in listening to the conference call may do so by dialing (877) 407-3036 for domestic callers or (201) 378-4919 for international callers, using Conference ID: 13581989. A live webcast of the event will be available on the “Investors” section of the company’s website at: www.eksobionics.com.
A replay of the call will be available for two weeks by dialing (877) 660-6853 for domestic callers or (201) 612-7415 for international callers and using Conference ID: 13581989. The webcast will also be available on the company’s website for one month following the completion of the call.
About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
Media Contact: Carrie Yamond / Rajni Dhanjani 212-867-1788 [email protected] Investor Contact: Debbie Kaster 415-937-5403 [email protected]
